A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles
Open to Enrollment
This research study is for newly diagnosed multiple myeloma patients who are candidates for systemic therapy that includes an IMiD (for example, lenalidomide, pomalidomide or thalidomide) and/or a proteasome inhibitor (for example, bortezomib, carfilzomib) but who have not yet started treatment. Patients who have already started treatment for myeloma are not eligible for this study.
The purpose of this study is to collect, store and analyze blood and bone marrow samples and health information from newly diagnosed multiple myeloma patients at the time of diagnosis and then at different time points during their disease. There are no drug treatments being given as part of this study.
The study is being conducted because we hope that having a better understanding of multiple myeloma will allow the development of more effective drugs with fewer side effects for patients with myeloma.
On study, participants will undergo procedures for the collection of blood and bone marrow samples. Participants will be in the study for approximately 5 years, and possibly longer.
Follow the Myeloma Center online:
Disease Status and/or Stage
Untreated Multiple Myeloma
Multiple Myeloma Research Foundation
- Men and women age 18 and older
- Newly diagnosed with multiple myeloma
- Is a candidate for systemic therapy that includes and IMID and/or proteasome inhibitor
- Has not yet started systemic therapy for multiple myeloma
- Detailed eligibility reviewed when you contact the study team
- The Myeloma Center
- (212) 746-3964
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
For general inquiries, or if you need assistance finding a study, please contact:
Tel: (646) 962-8232